VIEKIRA PAK (COPACKAGED) - (250MG;12.5MG, 75MG, 50MG ; Tablet)

Generic Name	DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR	**Innovator**	Abbvie
Dosage	250MG;12.5MG, 75MG, 50MG ; Tablet	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	VIEKIRA PAK is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV): • genotype 1b without cirrhosis or with compensated cirrhosis • genotype 1a without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.